NextCure, Inc. — Director's Dealing 2019

May 9, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NextCure, Inc. (NXTC)
CIK: 0001661059
Period of Report: 2019-05-08

Reporting Person: Khuong Chau Quang (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock	$		Common Stock (445866)		Indirect
Series A-2 Preferred Stock	$		Common Stock (743110)		Indirect
Series A-3 Preferred Stock	$		Common Stock (729599)		Indirect
Series B-1 Preferred Stock	$		Common Stock (442438)		Indirect

Footnotes

F1: The reported securities are convertible into shares of Common Stock on a 1-for-8.0338 basis at the holder's election, will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering, and have no expiration date.

F2: OrbiMed Capital GP VI LLC ("GP VII") is the general partner of OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is an employee of OrbiMed Advisors. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors and the Reporting Person disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein, if any.